Quarterly and annual results disclosed under 8-K Item 2.02.
Global Indemnity Group, LLC reported financial results for the year ended December 31, 2025.
“On March 10, 2026, Global Indemnity Group, LLC (the “Company”) issued a press release and held a conference call announcing the Company’s financial results for the year ended December 31, 2025.”
Vera Bradley, Inc. reported the fiscal year ended January 31, 2026 results: revenue $269.7 million, net income ($32.7) million, EPS ($1.17) per diluted share. Guidance initiated.
“Consolidated net revenues totaled $269.7 million, compared to $318.8 million for Fiscal 2025. Net loss from continuing operations totaled ($32.7) million, or ($1.17) per diluted share.”
Vera Bradley, Inc. reported the fourth quarter ended January 31, 2026 results: revenue $84.9 million, net income $2.7 million, EPS $0.09 per diluted share. Guidance initiated.
“Consolidated net revenues from continuing operations totaled $84.9 million compared to $86.4 million in the prior year fourth quarter ended February 1, 2025. Vera Bradley, Inc.’s net income from continuing operations totaled $2.7 million, or $0.09 per diluted share.”
CION Investment Corp reported the fourth quarter ended December 31, 2025 results: revenue $53.8 million, net income $ (41,120 ), EPS $(0.80) per share.
“outstanding 51,616,723 52,065,707 Distributions declared per share $ 0.36 $ 0.36 Total investment income for the three months ended December 31, 2025 and September 30, 2025 was $53.8 million and $78.7 million, respectively. The decrease in total investment income was primarily driven by lower interest income earned as a result of certain investment restructurings and”
PagerDuty, Inc. reported the full year of fiscal 2026 ended January 31, 2026 results: revenue $492.5 million, net income $173.9 million, EPS $1.87.
“Full Year Fiscal 2026 Financial Highlights • Revenue was $492.5 million, an increase of 5.4% year over year. • Operating income was $5.8 million; operating margin was 1.2%. • Non-GAAP operating income was $121.1 million; non-GAAP operating margin was 24.6%. • Net income was $173.9 million, representing the Company's first full year of GAAP profitability. • Net income per diluted share attributable to PagerDuty, Inc. common stockholders was $1.87. • Non-GAAP net income per diluted share attributable to PagerDuty, Inc. common stockholders was $1.16. • Net cash provided by operating activities was $114.9 million, with free cash flow of $102.7 million. • Cash, cash equivalents, and investments were $469.8 million as of January 31, 2026.”
PagerDuty, Inc. reported the fourth quarter of fiscal 2026 ended January 31, 2026 results: revenue $124.8 million, net income $11.0 million, EPS $0.12.
“Fourth Quarter Fiscal 2026 Financial Highlights • Revenue was $124.8 million, an increase of 2.7% year over year. • Operating income was $4.5 million; operating margin was 3.6%. • Non-GAAP operating income was $29.8 million; non-GAAP operating margin was 23.9%. • Net income was $11.0 million, representing the Company's third consecutive quarter of GAAP profitability. • Net income per diluted share attributable to PagerDuty, Inc. common stockholders was $0.12. • Non-GAAP net income per diluted share attributable to PagerDuty, Inc. common stockholders was $0.29. • Net cash provided by operating activities was $25.4 million, with free cash flow of $22.6 million.”
SentinelOne, Inc. reported fiscal year ended January 31, 2026 results: revenue $1,001.3 million.
“Total revenue increased 22% to $1,001.3 million, compared to $821.5 million.”
SentinelOne, Inc. reported fourth quarter ended January 31, 2026 results: revenue $271.2 million.
“Total revenue increased 20% to $271.2 million, compared to $225.5 million.”
Village Farms International, Inc. reported financial results for the fiscal year ended December 31, 2025.
“On March 12, 2026, Village Farms International, Inc. (the “Company” or “Village Farms”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
Village Farms International, Inc. reported financial results for the fourth quarter ended December 31, 2025.
“On March 12, 2026, Village Farms International, Inc. (the “Company” or “Village Farms”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025.”
BUTLER NATIONAL CORP reported the third quarter ended January 31, 2026 results: revenue $26.9 million, net income $6.7 million, EPS $0.10.
“BUTLER NATIONAL CORPORATION ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS - Revenue increased 27% to $26.9 million - Operating income increased 129% to $9.2 million - Net income increased 98% to $6.7 million - Earnings per share increased to $0.10 from $0.05”
Elicio Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $39.5 million, EPS $2.58.
“Net loss for 2025 was $39.5 million, compared to $51.9 million for 2024. Net loss for 2025 includes $1.9 million of non-cash other expense resulting from the change in fair value of the warrant liability. Net loss per share for 2025 was $2.58, compared to $4.25 for 2024.”
El Pollo Loco Holdings, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $123.5 million, net income $6.5 million, EPS $0.22 per diluted share.
“Highlights for the fourth quarter ended December 31, 2025 compared to the fourth quarter ended December 25, 2024 were as follows: ● Total revenue was $123.5 million compared to $114.3 million. ● System-wide comparable restaurant sales (1) increased by 2.1%. ● Income from operations was $10.3 million compared to $9.0 million. ● Restaurant contribution (1) was $17.9 million, or 17.5% of company-operated restaurant revenue, compared to $16.0 million, or 16.7% of company-operated restaurant revenue. ● Net income was $6.5 million, or $0.22 per diluted share, compared to net income of $6.0 million, or $0.20 per diluted share.”
Seres Therapeutics, Inc. reported the full year 2025 results: net income Net income from continuing operations was $5.7 million.
“Net income from continuing operations was $5.7 million for the full year 2025, as compared to a net loss from continuing operations of $125.8 million for 2024.”
Seres Therapeutics, Inc. reported the fourth quarter of 2025 results: net income Net loss from continuing operations was $15.3 million.
“Net loss from continuing operations was $15.3 million for the fourth quarter of 2025, as compared to a net loss from continuing operations of $15.7 million for the same period in 2024.”
JOINT Corp reported the full year ended December 31, 2025 results: revenue $54.9 million, net income $2.9 million.
“Full Year Revenues of $54.9 Million, Net Income of $2.9 Million and a 13.9% Increase in Adjusted EBITDA to $13.0 Million”
JOINT Corp reported the fourth quarter ended December 31, 2025 results: revenue $15.2 million, net income $1.0 million, EPS $0.07 per diluted share.
“Revenue increased 3.1% to $15.2 million, compared to $14.7 million in the fourth quarter of 2024.”
Corvus Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 12, 2026, Corvus Pharmaceuticals, Inc. issued a press release regarding, among other matters, its financial results for the fourth quarter and full year ended December 31, 2025 and its financial position as of December 31, 2025, and provided a business update.”
Health Catalyst, Inc. reported the year ended December 31, 2025 results: revenue $311.1 million, net income $ (177,974).
“We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million,”
Health Catalyst, Inc. reported the quarter ended December 31, 2025 results: revenue $ 74,679, net income $ (91,025).
“Months Ended December 31, Year over Year Change 2025 2024 2025 2024 GAAP Financial Measures: (in thousands, except percentages) (in thousands, except percentages) Total revenue $ 74,679 $ 79,606 (6)% $ 311,136 $ 306,584 1% Gross profit $ 31,385 $ 28,618 10% $ 120,356 $ 114,503 5% Gross margin 42.0 % 35.9 % 38.7 % 37.3 % Net loss $ (91,025) $ (20,673) (340)% $”
OnKure Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income $13.5 million, EPS $0.99 per share.
“Net loss and net loss per share for the fourth quarter of 2025 were $13.5 million, or $0.99 per share”
ServiceTitan, Inc. reported Full Fiscal Year 2026 results: revenue $961.0.
“Fiscal Fourth Quarter 2026 Fiscal Fourth Quarter 2025 Full Fiscal Year 2026 Full Fiscal Year 2025 (in millions, except percentages, GTV and active customers) Gross transaction volume (“GTV”) ( in billions ) (1) $19.8 $17.0 $82.1 $68.5 YOY GTV growth 16% 26% 20% 23% Total revenue $254.0 $209.3 $961.0 $771.9”
ServiceTitan, Inc. reported Fiscal Fourth Quarter 2026 results: revenue $254.0.
“Fiscal Fourth Quarter 2026 Fiscal Fourth Quarter 2025 Full Fiscal Year 2026 Full Fiscal Year 2025 (in millions, except percentages, GTV and active customers) Gross transaction volume (“GTV”) ( in billions ) (1) $19.8 $17.0 $82.1 $68.5 YOY GTV growth 16% 26% 20% 23% Total revenue $254.0 $209.3 $961.0 $771.9”
Bolt Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $7.7 million.
“Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively”
Bolt Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.
“Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively”
Runway Growth Finance Corp. reported Fiscal year ended December 31, 2025 results: revenue $137.3 million, net income $56.9 million, EPS $1.55 per share.
“Fiscal Year 2025 Highlights • Total investment portfolio of $927.4 million at fair value • Total investment income of $137.3 million • Net investment income of $56.9 million, or $1.55 per share • Net asset value of $485.0 million, or $13.42 per share • Total investment fundings of $261.6 million: $86.4 million in seven new portfolio companies, $168.5 million in ten existing portfolio companies, and $6.7 million in Runway-Cadma I LLC • Aggregate proceeds of $383.5 million in principal prepayments and $11.6 million from scheduled amortizations, and $38.6 million in sale proceeds from equity • Low credit loss ratio of an average 10 basis points per year on a gross basis and an average 7 basis points per year on a net (debt and equity) basis, based on cumulative commitments since inception”
Runway Growth Finance Corp. reported Fourth quarter ended December 31, 2025 results: revenue $30.0 million, net income $11.6 million, EPS $0.32 per share.
“Fourth Quarter 2025 Highlights • Total investment income of $30.0 million • Net investment income of $11.6 million, or $0.32 per share • Net asset value of $485.0 million, or $13.42 per share • Dollar-weighted annualized yield on debt investments of 14.2% • Seven investments completed in new and existing portfolio companies, representing $42.9 million in funded investments • Aggregate proceeds of $75.6 million in principal prepayments, $2.2 million from scheduled amortizations, and $0.3 million in sale proceeds from equity”
Zedge, Inc. reported second quarter fiscal 2026 ended January 31, 2026 results: revenue $8.3 million, net income ($2.3) million, EPS ($0.18).
“results across total revenue, advertising and subscription revenue, active subscriptions 1 , ARPMAU 1 , Zedge Premium GTV 1 Revenue increased 18% year over year to $8.3 million Subscription revenue increased 33%, and active subscriptions grew 49% to nearly 1.2 million ARPMAU increased 48% to a quarterly record of $0.115; Zedge Premium GTV increased 16%”
SenesTech, Inc. reported Full year ended December 31, 2025 results: net income $6.4 million.
“Revenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company’s overall e-commerce channels despite the impact associated with the Company’s transition to directly managing Amazon sales of Evolve ® Rat and Evolve Mouse.”
Once Upon a Farm, PBC reported the year ended December 31, 2025 results: revenue $240.7 million, net income ($17.2 million).
“Full Year 2025 Financial Highlights Compared to Prior Year • Net sales increased 53.5% to $240.7 million • Gross margin of 42.3% compared to 43.6% • Net loss of $17.2 million compared to a net loss of $23.8 million • Adjusted EBITDA 1 of $2.1 million compared to a loss of $3.7 million”
Once Upon a Farm, PBC reported the fourth quarter ended December 31, 2025 results: revenue $64.0 million, net income $22.5 million.
“Fourth Quarter 2025 Financial Highlights Compared to Prior Year Period • Net sales increased 30.1% to $64.0 million • Gross margin of 47.7% compared to 46.7% • Net income of $22.5 million compared to a net loss of $12.3 million • Adjusted EBITDA 1 of $6.6 million compared to $2.2 million”
Korro Bio, Inc. reported the fiscal year ended December 31, 2025 results: revenue $6.4 million.
“There was $6.4 million of collaboration revenue for the year ended December 31, 2025, as compared to $2.3 million for the year ended December 31, 2024.”
Korro Bio, Inc. reported financial results for the fourth quarter ended December 31, 2025.
“Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.”
Funko, Inc. reported the fiscal year ended December 31, 2025 results: revenue $908.2 million, net income $67.4 million, EPS $1.24 per share. Guidance initiated.
“Full-Year Financial Results Summary: 2025 vs 2024 • Net sales were $908.2 million compared with $1.05 billion • Gross profit was $351.3 million, equal to gross margin of 38.7%. This compares with $434.5 million, equal to gross margin of 41.4% • SG&A expenses were $337.7 million compared with $359.0 million • Net loss was $67.4 million , or $1.24 per share, compared with $14.7 million , or $0.28 per share”
Funko, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $273.1 million, net income $0.2 million, EPS $0.00 per share. Guidance initiated.
“Net sales were $273.1 million compared with $293.7 million • Gross profit was $111.6 million, equal to gross margin of 40.9%, compared with $124.4 million, equal to gross margin of 42.4% • SG&A expenses were $90.9 million compared with $102.8 million • Net loss was $0.2 million , or $0.00 per share, compared with $1.5 million , or $0.03 per share”
Adicet Bio, Inc. reported three months ended December 31, 2025 results: net income $30.5 million, EPS $2.94 per basic and diluted share.
“Net loss for the three months ended December 31, 2025 was $30.5 million, or a net loss of $2.94 per basic and diluted share”
Allogene Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $190.9 million, EPS $0.87 per share.
“For the full year of 2025, net loss was $190.9 million, or $0.87 per share, including non-cash stock-based compensation expense of $37.6 million and non-cash impairment of long-lived asset expense of $2.4 million.”
Allogene Therapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: net income $38.8 million, EPS $0.17 per share.
“Net loss for the fourth quarter of 2025 was $38.8 million, or $0.17 per share, including non-cash stock-based compensation expense of $8.1 million.”
IN8BIO, INC. reported financial results for fourth quarter and fiscal year ended December 31, 2025.
“On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025.”
Ascend Wellness Holdings, Inc. reported FY 2025 results: revenue $500.6 million, net income $118.2 million.
“Total net revenue was $500.6 million compared to $561.6 million in full year 2024 (“FY 2024”).”
Ascend Wellness Holdings, Inc. reported Q4 2025 results: revenue $120.5 million, net income $48.7 million.
“Total net revenue was $120.5 million compared to $124.7 million in the third quarter of 2025 (“Q3 2025”).”
Karat Packaging Inc. reported First Quarter and Full Year 2026 results: revenue Net sales for the 2026 first quarter expected to increase by 8 to 10 percent from the prior-year quarter. Net sales for. Guidance initiated.
“Guidance • Net sales for the 2026 first quarter expected to increase by 8 to 10 percent from the prior-year quarter. • Gross margin for the 2026 first quarter expected to be between 34 and 36 percent. • Adjusted EBITDA margin for the 2026 first quarter expected to be between 9 and 11 percent. • Net sales for full-year 2026 expected to increase by low double-digits from the prior year. • Gross margin and adjusted EBITDA margin for full year 2026 expected to continue to improve compared with the prior year, under current global tariff policy.”
Karat Packaging Inc. reported Fourth Quarter 2025 results: revenue $115.6 million, net income $7.2 million, EPS $0.34 per diluted share.
“Fourth Quarter 2025 Financial Results Net sales for the 2025 fourth quarter increased 13.7 percent to $115.6 million, from $101.6 million in the prior-year quarter. The increase primarily reflected $8.2 million in volume and a $6.3 million favorable impact from pricing and product mix. Cost of goods sold for the 2025 fourth quarter increased 23.4 percent to $76.3 million, from $61.8 million in the prior-year quarter. Product costs increased $6.1 million due to sales growth, partially offset by more favorable vendor pricing and product mix. Within import costs, duty and tariff costs increased $8.4 million, reflecting the overall higher tariff rates and a $0.4 million adjustment to the duty reserve previously recorded on certain imports. Gross profit for the 2025 fourth quarter was $39.3 million, compared with $39.8 million in the prior-year quarter. Gross margin for the 2025 fourth quarter was 34.0 percent, compared with 39.2 percent in the prior-year quarter, reflecting the expected im”
Erasca, Inc. reported Q4 2025 results: net income -29.1 million, EPS -0.10.
“Net loss was $29.1 million, or $(0.10) per basic and diluted share, for the quarter ended December 31, 2025”
MBX Biosciences, Inc. reported the full year ended December 31, 2025 results: net income $87.0 million.
“Net loss for the full year ended December 31, 2025 was $87.0 million”
MBX Biosciences, Inc. reported the three months ended December 31, 2025 results: net income $22.1 million.
“Net loss for the three months ended December 31, 2025, was $22.1 million”
TerrAscend Corp. reported Full Year 2025 results: revenue Net Revenue was $260.6 million, net income GAAP Net Loss from continuing operations was $24.5 million.
“Full Year 2025 Financial Highlights • Net Revenue was $260.6 million, compared to $268.1 million in 2024. • Gross Profit Margin was 52.3%, compared to 50.7% in 2024. • GAAP Net Loss from continuing operations was $24.5 million, compared to $20.9 million in 2024.”
TerrAscend Corp. reported Fourth Quarter 2025 results: revenue Net Revenue was $66.1 million, net income GAAP Net Loss from continuing operations was $0.5 million.
“Fourth Quarter 2025 Financial Highlights • Net Revenue was $66.1 million, compared to $65.1 million in Q3 2025. • Gross Profit Margin was flat at 52.1%, compared to Q3 2025. • GAAP Net Loss from continuing operations was $0.5 million, compared to net loss of $9.9 million in Q3 2025.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.